In fact, companies have invested over $20 billion in research into such drugs since the 1990s. The reason why is clear: the market lifestyle ... cessation and had sales of $174m in 2000.

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

AbbVie shares rose 5.5% Friday, after the company hiked its sales forecasts for two key drugs. The company reported fourth-quarter revenue and earnings above Wall Street's estimates, and forecast ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

It was the second time in a year its sales had come up short due to issues it attributed ... which holds Lilly shares. Zepbound's market share stands at just over 50%, according to IQVIA data shared ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued ... concerned about an obesity market slowdown, as well as ...